3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Histiocytosis
1
Head and Neck Neoplasms
1
Glioblastoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
Immunotherapy
×
Clear all
No trials found.